CoChat

Long interspersed nuclear element‐1 hypomethylation is a potential biomarker for the prediction of response to oral fluoropyrimidines in microsatellite stable and CpG island methylator phenotype‐negative colorectal cancer

Open access
Kawakami, Kazuyuki, Matsunoki, Aika, Kaneko, Mami, Saito, Kenichiro, Watanabe, Go, Minamoto, Toshinari · 2011 · Cancer Science
Cited by 75

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Abstract

We investigated the clinical value of methylation of long interspersed nuclear element‐1 (LINE‐1) for the prognosis of colorectal cancer (CRC) and for the survival benefit from adjuvant chemotherapy with oral fluoropyrimidines. LINE‐1 methylation in tumor DNA was measured by quantitative methylation‐specific PCR in 155 samples of stage II and stage III CRC. The presence of microsatellite instability and CpG island methylator phenotype (CIMP) were assessed and 131 microsatellite stable/CIMP− cases were selected for survival analysis, of which 77 patients had received postoperative adjuvant chemotherapy with oral fluoropyrimidines. The CRC cell lines were used to investigate possible mechanistic links between LINE‐1 methylation and effects of 5‐fluorouracil (5‐FU). High LINE‐1 methylation was a marker for better prognosis in patients treated by surgery alone. Patients with low LINE‐1 methylation who were treated with adjuvant chemotherapy survived longer than those treated by surgery alone, suggestive of a survival benefit from the use of oral fluoropyrimidines. In contrast, a survival benefit from chemotherapy was not observed for patients with high LINE‐1 methylation. The CRC cell lines treated with 5‐FU showed increased expression of LINE‐1 mRNA. This was associated with upregulation of the phospho‐histone H2A.X in cells with low LINE‐1 methylation, but not in cells with high LINE‐1 methylation. The 5‐FU‐mediated induction of phospho‐histone H2A.X, a marker of DNA damage, was inhibited by knockdown of LINE‐1. These results suggest that LINE‐1 methylation is a novel predictive marker for survival benefit from adjuvant chemotherapy with oral fluoropyrimidines in CRC patients. This finding could be important for achieving personalized chemotherapy. (Cancer Sci 2011; 102: 166–174)

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1349-7006.2010.01776.x

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 8 references

Cited by

See all 75

Metadata

Authors
Kawakami, K., Matsunoki, A., Kaneko, M., Saito, K., Watanabe, G., & Minamoto, T.
Venue
Cancer Science
Publisher
Wiley
Published
2010-11-19
Volume
102
Issue
1
Pages
166-174
ISSN
  • 1347-9032 (ISSN-L)
  • 1349-7006
OpenAlex
W1967205042
Cited by
75
References
8
FWCI
3.85
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Long interspersed nuclear element‐1 hypomethylation is a potential biomarker for the prediction of response to oral fluoropyrimidines in microsatellite stable and CpG island methylator phenotype‐negative colorectal cancer. https://app.cochat.ai/papers/10.1111/j.1349-7006.2010.01776.x
The paper
Kawakami, K., Matsunoki, A., Kaneko, M., Saito, K., Watanabe, G., & Minamoto, T. (2011). Long interspersed nuclear element‐1 hypomethylation is a potential biomarker for the prediction of response to oral fluoropyrimidines in microsatellite stable and CpG island methylator phenotype‐negative colorectal cancer. Cancer Science. https://doi.org/10.1111/j.1349-7006.2010.01776.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.